GlassScriptPhysician profile
Brian A Price
NPI 1962536953
$24,438.27
in general payments reported to CMS, 2019-2025
35 companies · $2,614 in 2025
The $2,614 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,284 · 2020: $2,076 · 2021: $1,647 · 2022: $13K · 2023: $609 · 2024: $261 · 2025: $2,614.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,085 · Travel and Lodging: $1,399.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,085.13 |
| Travel and Lodging | $1,398.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Penumbra, INC. | $9,475.30 | 2021-2025 | Indigo System |
| Abbott Laboratories | $5,504.80 | 2020-2025 | Perclose Proglide, Esprit, Dragonfly Opstar |
| Cardiovascular Systems INC. | $2,060.36 | 2019-2023 | |
| Medtronic Vascular, INC. | $1,622.31 | 2019 | |
| Boston Scientific Corporation | $909.98 | 2020-2025 | Eluvia |
| Ekos Corporation | $838.17 | 2019 | |
| Inari Medical, INC. | $624.35 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $583.02 | 2019-2023 | Xarelto |
| Novartis Pharmaceuticals Corporation | $495.80 | 2019-2024 | |
| Amgen INC. | $342.92 | 2019-2022 | |
| Medtronic, INC. | $279.50 | 2021-2025 | Onyx Frontier, Micra |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $213.22 | 2019-2022 | |
| Teleflex LLC | $206.57 | 2019 | |
| Sanofi-Aventis U.S. LLC | $176.17 | 2019-2023 | |
| Esperion Therapeutics, INC. | $171.75 | 2020-2022 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Chiesi USA, INC. | $140.34 | 2019-2023 | Kengreal |
| Abiomed | $134.03 | 2019 | |
| Livanova USA, INC. | $129.15 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $99.59 | 2019-2022 | |
| Pfizer INC. | $67.20 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $52.81 | 2020-2022 | |
| Novo Nordisk INC | $38.84 | 2019-2021 | |
| Philips North America LLC | $38.60 | 2024 | (Bq9) Coronary Ivus |
| Lundbeck LLC | $36.06 | 2019 | |
| Merck Sharp & Dohme LLC | $28.19 | 2021-2022 | |
| Alnylam Pharmaceuticals INC. | $22.41 | 2021 | |
| Becton, Dickinson and Company | $20.89 | 2025 | Lifestream |
| E.R. Squibb & Sons, L.L.C. | $19.67 | 2022 | |
| Stryker Corporation | $18.29 | 2025 | Artix Mt |
| Cardinal Health 200 LLC | $16.29 | 2019 | |
| Biotronik INC. | $15.95 | 2022 | |
| Portola Pharmaceuticals, LLC | $14.89 | 2019 | |
| Verge Medical, INC. | $14.26 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $13.81 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $12.78 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Price listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.